Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 591-600 of 639 results
Adv Drug Deliv Rev, 2019 • August 1, 2019
This review article summarizes nanomaterial fabrication and therapeutic effects achieved by nanoscale systems in pre-clinical studies of spinal cord injury (SCI). The review specifically discusses str...
KEY FINDING: Nanocarriers enable localized, slow, and sustained delivery of therapeutics at the site of injury, overcoming limitations of systemic administration.
Frontiers in Oncology, 2019 • February 1, 2019
This systematic review analyzed 33 studies on molecular targeted therapy (MTT) for chordoma, a rare bone malignancy affecting the spine and skull base. The review identified imatinib and erlotinib as ...
KEY FINDING: Imatinib and erlotinib were the most frequently used molecular targeted inhibitors (MTIs) for chordoma.
Life Science Alliance, 2019 • March 25, 2019
This study successfully established a human SMN2-GFP reporter line for drug screening, which allowed the identification of Z-FA-FMK, a cysteine protease inhibitor, as a potential therapeutic agent for...
KEY FINDING: The study established a human SMN2-GFP reporter line for drug screening, which effectively identified compounds that increase functional SMN protein levels.
BioMed Research International, 2019 • June 2, 2019
The study investigates the therapeutic potential of nAG protein in a rat model of liver fibrosis induced by carbon tetrachloride (CCL4). Results showed that nAG treatment significantly reduced serum l...
KEY FINDING: CCL4 treatment significantly increased serum levels of hyaluronic acid, PDGF-AB, TIMP-1, laminin, procollagen III N-terminal peptide, and collagen IV-alpha 1 chain.
Frontiers in Pharmacology, 2019 • July 17, 2019
This study investigates the mechanism by which Bu Shen Yi Sui formula (BSYS), a traditional Chinese medicine, promotes axonal regeneration in multiple sclerosis (MS) and its animal model, experimental...
KEY FINDING: BSYS-containing serum increased cell viability and levels of GAP-43, p-CREB, BDNF, TrkB, and p-PI3K in damaged SH-SY5Y cells.
Expert Opin Ther Targets, 2019 • September 1, 2019
Researchers have made significant progress in understanding the pathophysiology of SCI and in developing effective preclinical therapeutic strategies by targeting diverse cellular and molecular mechan...
KEY FINDING: Early surgical decompression appears to improve neurological function in preclinical and clinical studies.
Frontiers in Pharmacology, 2019 • October 16, 2019
The study demonstrates a novel role for FGF10 in improving sensory and motor functional recovery, enhancing axonal regrowth and remyelination, and increasing the expression of functional proteins afte...
KEY FINDING: FGF10 continuously enhances the recovery of locomotor and sensory function in acute PNI.
Stem Cell Research & Therapy, 2020 • January 9, 2020
The study aimed to assess the consistency, potency, and stability of PBMC secretome batches produced under GMP, by comparing different batches and analyzing physicochemical and biological parameters, ...
KEY FINDING: Inter-batch differences in the bioactive components and secretome properties were small despite considerable differences in protein concentrations and potencies between individual donor secretomes.
Materials Today Bio, 2021 • January 22, 2021
Spinal cord injury (SCI) is a devastating condition with limited effective therapies. Hydrogels, with their unique properties, offer a promising avenue for delivering therapeutic agents and promoting ...
KEY FINDING: Hydrogels can be derived from natural or synthetic sources, each offering distinct advantages. Natural sources provide biocompatibility and biodegradability, while synthetic sources offer high water absorption and a wider range of chemical properties.
Neural Development, 2020 • January 5, 2020
The Nogo pathway stabilizes CNS circuitry, limiting plasticity and functional recovery after spinal cord damage. Anti-Nogo antibodies improve anatomical and functional recovery, particularly with acut...
KEY FINDING: Anti-Nogo antibodies have consistently demonstrated improvement in motor function recovery in rats and primates, including fine finger control.